论文部分内容阅读
目的 评价苯那普利对 2型糖尿病患者尿铜蓝蛋白 (Cp)及尿白蛋白 (Alb)的影响。 方法 84例 2型糖尿病患者均分为对照组、控制血压组和苯那普利组。记录及测定受试者的年龄、性别、糖尿病病程、血压、腰围、臀围、腰臀比、身高、体重、体重指数、血糖、糖化血红蛋白、胰岛素、尿素氮、肌酐、尿酸、血脂、血白蛋白 ,并留取晨尿测定铜蓝蛋白、白蛋白及肌酐 (Cr) ,随访 6个月后复查上述指标 ,比较尿Alb/Cr及尿Cp/Cr的变化。 结果 对照组无明显变化 ;控制血压组及苯那普利组尿Alb/Cr和尿Cp/Cr水平均下降 ,苯那普利组尿Cp/Cr下降较控制血压组更明显 (P <0 .0 5 )。结论 苯那普利可降低尿Cp/Cr及尿Alb/Cr。
Objective To evaluate the effects of benazepril on urinary ceruloplasmin (CP) and urinary albumin (Alb) in type 2 diabetic patients. Methods Eighty-four patients with type 2 diabetes were divided into control group, controlled blood pressure group and benazepril group. The age, sex, duration of diabetes, blood pressure, waist circumference, hip circumference, waist-hip ratio, height, weight, body mass index, blood glucose, glycosylated hemoglobin, insulin, urea nitrogen, creatinine, uric acid, Protein and morning urine were collected for the determination of ceruloplasmin, albumin and creatinine (Cr). After 6 months of follow-up, the above indexes were examined and the changes of urinary Alb / Cr and urine Cp / Cr were compared. The results showed that there was no significant change in the control group. Urinary Alb / Cr and urinary Cp / Cr levels decreased in the controlled blood pressure group and the benazepril group. The decrease of urinary Cp / Cr in the benazepril group was more obvious than that in the control blood pressure group (P <0. 0 5). Conclusion benazepril can reduce urinary Cp / Cr and urine Alb / Cr.